Medizone International Delivers Initial AsepticSure Production Units To Canadian Distributor
San Francisco, California, September 12, 2012. Medizone International, Inc. (The Company) (MZEI:OB) (MZEI:QB) announced today that it has completed delivery of the first of its production AsepticSure disinfection systems to C3 Contamination Control Corporation. C3 is the AsepticSure Sales and Service Division of CanMedical, Medizone’s Canadian Distributor.
Medizone’s Chairman & CEO, Edwin Marshall stated, “while it has taken significantly longer to finalize the first run of production units than originally envisioned, we are pleased to report that robust and reliable systems have now been delivered to C3. These systems are being placed into immediate commercial service by our Canadian distributor. We also have a pending order from C3 for ongoing additional systems. This is in line with their business plan requirements for a steady increase in capacity for their service model, as well as sales to end users as a distributor.”
Additional news regarding favorable regulatory rulings for AsepticSure, anticipated production and sales ramp ups and other significant information will be published on Medizone’s website, tomorrow morning. Please see the Chairman’s Update on the website home page.
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: email@example.com
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com